NCT02127437: LIPS

Lanreotide In Polycystic Kidney Disease Study

Completed Phase 3 Last updated 8 April 2026

What this trial tests

Phase 3 trial testing Lanreotide in Autosomal Dominant Polycystic Kidney Disease (ADPKD in 159 participants. Completed in 31 July 2019.

Timeline

19 September 2014

Primary endpoint
31 July 2019

31 July 2019

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	159
Start date	19 September 2014
Primary completion	31 July 2019
Estimated completion	31 July 2019
Sites	1 location across France

Drugs / interventions tested

• Lanreotide (LANREOTIDE) — full drug profile →
• saline

Conditions studied

• Autosomal Dominant Polycystic Kidney Disease (ADPKD — all drugs for Autosomal Dominant Polycystic Kidney Disease (ADPKD →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Autosomal Dominant Polycystic Kidney Disease (ADPKD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to start in early 2014.

An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to 60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30 ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by repeated measures, in the overall population as well as in the two GFR stratus.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.
   Chebib FT, Torres VE. · · 2018 · cited 76× · PMID 30049849 · DOI 10.2215/cjn.03960318
2. Management of autosomal-dominant polycystic kidney disease-state-of-the-art.
   Müller RU, Benzing T. · · 2018 · cited 29× · PMID 30581561 · DOI 10.1093/ckj/sfy103
3. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
   Messchendorp AL, Casteleijn NF, Meijer E, Gansevoort RT. · · 2020 · cited 20× · PMID 31077332 · DOI 10.1093/ndt/gfz054
4. Metabolism-based approaches for autosomal dominant polycystic kidney disease.
   Bakaj I, Pocai A. · · 2023 · cited 9× · PMID 36876046 · DOI 10.3389/fmolb.2023.1126055
5. Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
   St Pierre K, Cashmore BA, Bolignano D, Zoccali C, et al · · 2024 · cited 7× · PMID 39356039 · DOI 10.1002/14651858.cd010294.pub3
6. Enteroendocrine cells and gut hormones as potential targets in the crossroad of the gut-kidney axis communication.
   Nery Neto JAO, Yariwake VY, Câmara NOS, Andrade-Oliveira V. · · 2023 · cited 2× · PMID 37927592 · DOI 10.3389/fphar.2023.1248757